LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Hypercholesterolemia
Interventions
DRUG

Ezetimibe and placebo

Placebo or three different doses of eprotirome added to ezetimibe treatment

DRUG

Eprotirome and ezetimibe

Placebo or three different doses of eprotirome added to ezetimibe treatment

Trial Locations (1)

Unknown

Karo Bio AB, Huddinge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Karo Bio AB

INDUSTRY